1.Application of visualized thermosensitive color-changing bolus in postmastectomy radiotherapy for breast cancer
Yong WANG ; Yanze SUN ; Wenmin HAN ; Jianjun QIAN ; Peifeng ZHAO ; Liesong CHEN ; Yaqun ZHU ; Ye TIAN
Chinese Journal of Radiological Medicine and Protection 2025;45(5):431-437
Objective:To explore the feasibility and advantages of applying visualized thermosensitive color-changing bolus in postmastectomy radiotherapy (PMRT) for breast cancer.Methods:Forty patients with breast cancer treated with PMRT in the Second Affiliated Hospital of Soochow University from June 2023 to June 2024 were prospectively selected. They were randomly divided into test and control groups (also referred to as groups A and B, respectively), with 20 patients in each group. Group A, underwent two CT scans: the first scan without bolus (image A1) and the second scan with visualized thermosensitive color-changing bolus (image A2). They were treated with visualized thermosensitive color-changing bolus. Group B also underwent two CT scans: the first scan without bolus (image B1) and the second scan with conventional commercial bolus (image B2), and then were treated with conventional commercial bolus. In the radiotherapy planning, images A1 and A2 were designed as A1-Plan and A2-Plan, and A3-Plan was created by transferring the A1-Plan onto image A2. Images B1 and B2 were designed as B1-Plan and B2-Plan, and B3-Plan was created by transferring the B1-Plan onto image B2. The radiation fields and target optimization functions were identical. The dosimetric differences and skin toxicity reactions between different plans were compared.Results:In Group A, A1-Plan and A2-Plan manifested no statistically significant differences ( P > 0.05) in the doses to organs at risk (OARs), including the ipsilateral lung ( V5 Gy, V10 Gy, V20 Gy), heart ( Dmean), contralateral breast ( Dmean), and skin ( Dmax and Dmean), target homogeneity index (HI), conformity index (CI), prescription dose volume ( V50 Gy), depth of maximum dose ( Dmax), and monitor unit (MU). In Group B, B3-Plan compared to B1-Plan showed reduced V50 Gy (89.9% vs. 95%), HI (0.153 vs. 0.136), and CI (0.817 vs. 0.810), while the two plans displayed no statistically significant differences in doses to OARs. In contrast, A3-Plan and B3-Plan exhibited statistically significant differences ( t = 2.78, 2.29, -0.47, 0.51, 3.13, P < 0.05) in V50 Gy (94.05% vs. 89.90%), Dmax (5 665.4 cGy vs. 5 632.7 cGy), HI (0.148 vs. 0.163), CI (0.83 vs. 0.82), and skin Dmean (5 153.6 cGy vs. 5 048.2 cGy). Compared to the conventional commercial bolus of the same thickness, the visualized thermosensitive color-changing bolus yielded a significantly reduced air cavity volume (3 833 mm 3vs. 21 498 mm 3,t = -9.65, P < 0.05). Both groups experienced only grade I skin toxicity reactions. Conclusions:Compared to the conventional commercial bolus of the same thickness, the visualized thermosensitive color-changing bolus shows a more effective dosimetric distribution in terms of target coverage, HI, and CI, a higher fit to the skin, highly visualized air cavity, and higher positional repeatability in fractionated radiotherapy, demonstrating high practicality and safety.
2.Analysis of epidemiological trends from 1990 to 2021 of liver cancer in China
Yanze HAN ; Huixin SUN ; Dongsheng XU
Chinese Journal of Hepatology 2025;33(2):143-150
Objective:To analyze and predict the incidence and mortality rate condition from 1990 to 2021 and 2022 to 2045 in China so as to evaluate the impact of different ages, periods, and birth cohorts on liver cancer.Methods:The 2021 Global Burden of Disease Study database was used. The variation trend of standardized incidence and mortality of liver cancer was analyzed using the Joinpoint regression model. The age, period, and cohort effects were used to explore liver cancer incidence and mortality rates based on the age-period-cohort model. The Nordpred prediction model was used to fit the trend of standardized incidence and mortality rates in liver cancer. Simultaneously, the standardized incidence and mortality rates were predicted from 2022 to 2045 for liver cancer. Joinpoint regression analysis was performed using the GBDASR_aapc package.Results:The standardized incidence and mortality rate from 1990 to 2021 of liver cancer showed an overall downward trend year by year in China ( P<0.01). Age, period, and cohort effects were all risk factors for the incidence of liver cancer. The incidence and mortality rates both increase with age, reaching a peak in the 85~89 age group. The risk of HCC morbidity and mortality was higher in the population of early-stage birth cohorts. Although the period effect showed a slight upward trend over time, the change in the period effect was relatively small. The incidence and mortality rates after the age of 40 were significantly higher in males than those of females. The prediction results showed that the standardized incidence and mortality rates from 2022 to 2045 of liver cancer have had a downward trend in China. Conclusion:The standardized incidence and mortality rates of liver cancer show an overall downward trend in China, but the burden in males is still high. Therefore, liver cancer prevention and control work in the future should continue to strengthen intervention in high-risk groups.
3.Application of visualized thermosensitive color-changing bolus in postmastectomy radiotherapy for breast cancer
Yong WANG ; Yanze SUN ; Wenmin HAN ; Jianjun QIAN ; Peifeng ZHAO ; Liesong CHEN ; Yaqun ZHU ; Ye TIAN
Chinese Journal of Radiological Medicine and Protection 2025;45(5):431-437
Objective:To explore the feasibility and advantages of applying visualized thermosensitive color-changing bolus in postmastectomy radiotherapy (PMRT) for breast cancer.Methods:Forty patients with breast cancer treated with PMRT in the Second Affiliated Hospital of Soochow University from June 2023 to June 2024 were prospectively selected. They were randomly divided into test and control groups (also referred to as groups A and B, respectively), with 20 patients in each group. Group A, underwent two CT scans: the first scan without bolus (image A1) and the second scan with visualized thermosensitive color-changing bolus (image A2). They were treated with visualized thermosensitive color-changing bolus. Group B also underwent two CT scans: the first scan without bolus (image B1) and the second scan with conventional commercial bolus (image B2), and then were treated with conventional commercial bolus. In the radiotherapy planning, images A1 and A2 were designed as A1-Plan and A2-Plan, and A3-Plan was created by transferring the A1-Plan onto image A2. Images B1 and B2 were designed as B1-Plan and B2-Plan, and B3-Plan was created by transferring the B1-Plan onto image B2. The radiation fields and target optimization functions were identical. The dosimetric differences and skin toxicity reactions between different plans were compared.Results:In Group A, A1-Plan and A2-Plan manifested no statistically significant differences ( P > 0.05) in the doses to organs at risk (OARs), including the ipsilateral lung ( V5 Gy, V10 Gy, V20 Gy), heart ( Dmean), contralateral breast ( Dmean), and skin ( Dmax and Dmean), target homogeneity index (HI), conformity index (CI), prescription dose volume ( V50 Gy), depth of maximum dose ( Dmax), and monitor unit (MU). In Group B, B3-Plan compared to B1-Plan showed reduced V50 Gy (89.9% vs. 95%), HI (0.153 vs. 0.136), and CI (0.817 vs. 0.810), while the two plans displayed no statistically significant differences in doses to OARs. In contrast, A3-Plan and B3-Plan exhibited statistically significant differences ( t = 2.78, 2.29, -0.47, 0.51, 3.13, P < 0.05) in V50 Gy (94.05% vs. 89.90%), Dmax (5 665.4 cGy vs. 5 632.7 cGy), HI (0.148 vs. 0.163), CI (0.83 vs. 0.82), and skin Dmean (5 153.6 cGy vs. 5 048.2 cGy). Compared to the conventional commercial bolus of the same thickness, the visualized thermosensitive color-changing bolus yielded a significantly reduced air cavity volume (3 833 mm 3vs. 21 498 mm 3,t = -9.65, P < 0.05). Both groups experienced only grade I skin toxicity reactions. Conclusions:Compared to the conventional commercial bolus of the same thickness, the visualized thermosensitive color-changing bolus shows a more effective dosimetric distribution in terms of target coverage, HI, and CI, a higher fit to the skin, highly visualized air cavity, and higher positional repeatability in fractionated radiotherapy, demonstrating high practicality and safety.
4.Analysis of epidemiological trends from 1990 to 2021 of liver cancer in China
Yanze HAN ; Huixin SUN ; Dongsheng XU
Chinese Journal of Hepatology 2025;33(2):143-150
Objective:To analyze and predict the incidence and mortality rate condition from 1990 to 2021 and 2022 to 2045 in China so as to evaluate the impact of different ages, periods, and birth cohorts on liver cancer.Methods:The 2021 Global Burden of Disease Study database was used. The variation trend of standardized incidence and mortality of liver cancer was analyzed using the Joinpoint regression model. The age, period, and cohort effects were used to explore liver cancer incidence and mortality rates based on the age-period-cohort model. The Nordpred prediction model was used to fit the trend of standardized incidence and mortality rates in liver cancer. Simultaneously, the standardized incidence and mortality rates were predicted from 2022 to 2045 for liver cancer. Joinpoint regression analysis was performed using the GBDASR_aapc package.Results:The standardized incidence and mortality rate from 1990 to 2021 of liver cancer showed an overall downward trend year by year in China ( P<0.01). Age, period, and cohort effects were all risk factors for the incidence of liver cancer. The incidence and mortality rates both increase with age, reaching a peak in the 85~89 age group. The risk of HCC morbidity and mortality was higher in the population of early-stage birth cohorts. Although the period effect showed a slight upward trend over time, the change in the period effect was relatively small. The incidence and mortality rates after the age of 40 were significantly higher in males than those of females. The prediction results showed that the standardized incidence and mortality rates from 2022 to 2045 of liver cancer have had a downward trend in China. Conclusion:The standardized incidence and mortality rates of liver cancer show an overall downward trend in China, but the burden in males is still high. Therefore, liver cancer prevention and control work in the future should continue to strengthen intervention in high-risk groups.
5.Analysis of the Evidence Map of Clinical Research on Treatment of Hyperlipidemia with Traditional Chinese Medicine
Wenjie HAN ; Chidao ZHANG ; Lanxin LI ; Yanze LIU ; Ruipeng WU ; Yipei AN ; Mingjun ZHU ; Xinlu WANG
Traditional Chinese Drug Research & Clinical Pharmacology 2024;35(10):1611-1620
Objective To comprehensively review the clinical research on the treatment of hyperlipidemia with traditional Chinese Medicine(TCM)through the evidence mapping,and to understand the distribution of evidence in this field. Methods Databases including CNKI,Wangfang,VIP,SinoMed,PubMed,Cochrane Library,and Embase were searched from January 2004 to December 2023 to collect clinical studies,systematic reviews/meta-analyses,guidelines and clinical pathways related to the treatment of hyperlipidemia with TCM. The results were analyzed and displayed in charts and graphs according to the screening criteria,and the Assessment of Multiple Systematic Reviews 2 (AMSTAR 2) tool and the Preferred Reporting Item for Systematic Review and Meta-analysis of Chinese herbal medicine (PRISMA-CHM) were used to evaluate the quality of the systematic review/meta-analysis. Results A total of 1223 studies were included in the analysis according to Population,Intervention,Comparison,Outcome and Study design(PICOS) principles,involving 920 RCTs,249 non-RCTs,49 systematic reviews/meta-analyses,and 5 guidelines/expert consensus. In recent years,the overall number of clinical research publications has shown a downward trend. Hyperlipidemia frequently occurs in middle-aged and elderly people,and age of onset tends to be younger. The sample size of randomized controlled studies is mostly concentrated in 60-300 cases. There are many types of clinical treatment regimens for the treatment of hyperlipidemia with TCM,among which TCM decoction (50.13%) and Chinese patent medicine (38.41%) account for a relatively high proportion,and TCM exercise therapy (0.51%) is the lowest treatment. Jiangzhi Decoction has attracted more attention in trial group of TCM decoction,while Xuezhikang Capsule has attracted more attention in trial group of Chinese patent medicine. In terms of methodological design,199 papers(21.63%) explicitly mentioned the method of generating random sequence,17 papers(1.85%) mentioned allocation concealment,37 papers (4.02%) mentioned blinding. The control group was dominated by the statins,including simvastatin and atorvastatin. The outcome indicators mainly include the total effective rate,TCM syndrome score,blood lipid level,coagulation index,and adverse reactions,while the attention of TCM characteristic efficacy,inflammation,oxidative stress,and vascular endothelial index were low. The methodological and reporting quality of the systematic review/Meta-analysis were generally not high. AMSTAR-2 evaluation was extremely low,and the average PRISMA-CHM score was 15. Conclusion TCM has certain advantages in the treatment of hyperlipidemia,but there is a lack of high-quality evidence-based proof,and more high-quality clinical studies are still needed to further provide evidence supports in the future. It has been suggested that more large-sample and multi-center clinical studies should be carried out in the future. We should formulate systematic reviews/Meta analysis and guidelines/expert consensus according to the guidelines of clinical practice issues,also consult international standards and regulations,enhance normativity and reliability to improve the quality of their evidence.
6.Actual measurement verification of dose calculation accuracy based on cone-beam CT images
Li CHEN ; Gang ZHOU ; Yanze SUN ; Qiliang PENG ; Jieguan HAN ; Ye TIAN
Chinese Journal of Radiation Oncology 2023;32(6):539-545
Objective:To evaluate the dose calculation accuracy of cone-beam CT (CBCT) image by actual measurement method.Methods:CBCT images of 60 patients in the Second Affiliated Hospital of Soochow University from September, 2021 to May, 2022 were retrospectively analyzed. CBCT images of full-fan and half-fan scanning of the head, half-fan scanning of the chest and pelvis were obtained by the Varian OBI system. Hounsfield unit - electron density (HU-ED) curves corresponding to the scanning conditions were established with CIRS electron density phantom. The radiotherapy plans were designed on the CBCT images, and the dose calculation results of the detection point were compared with the ionization chamber measurement results to analyze the dose error. Then, three-dimensional dose verification system was adopted to detect the accuracy of the CBCT image radiotherapy plans implementation process in 60 patients, and the accuracy of dose calculation was verified according to the D 99%, D mean, D 1% of target volume, D mean and D 1% of organs at risk (OAR), and the γ pass rate. Results:In point dose detection in phantom, the dose calculation errors of CBCT images in the above four scanning patterns were -1.06%±0.87%、-1.67%±0.86%, 0.91%±0.73%, -1.54%±0.90%, respectively. In dosimetric verification based on patients' CBCT image treatment plan, the mean difference of D mean, D 99%, and D 1% of planning target volume (PTV) in all scanning modes were not higher than 2%, and the D mean and D 1% differences of other OAR were not higher than 3%, except for the lens of patients in the head. The average γ values of target volume and OAR were less than 0.5 under the criteria of 3%/2 mm. Conclusions:Under the condition of correctly establishing HU-ED curves, intensity-modulated radiation therapy (IMRT) / volumetric-modulated arc therapy (VMAT) planning based on CBCT images can be employed to estimate and monitor the actual dose to target volume and OAR in adaptive radiotherapy. Full-fan scanning patterns can further improve the accuracy of dose calculation for the head of patients.
7.The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy.
Patrick Kwabena ODURO ; Xianxian ZHENG ; Jinna WEI ; Yanze YANG ; Yuefei WANG ; Han ZHANG ; Erwei LIU ; Xiumei GAO ; Mei DU ; Qilong WANG
Acta Pharmaceutica Sinica B 2022;12(1):50-75
The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling exert essential regulatory function in microbial-and onco-immunology through the induction of cytokines, primarily type I interferons. Recently, the aberrant and deranged signaling of the cGAS-STING axis is closely implicated in multiple sterile inflammatory diseases, including heart failure, myocardial infarction, cardiac hypertrophy, nonalcoholic fatty liver diseases, aortic aneurysm and dissection, obesity, etc. This is because of the massive loads of damage-associated molecular patterns (mitochondrial DNA, DNA in extracellular vesicles) liberated from recurrent injury to metabolic cellular organelles and tissues, which are sensed by the pathway. Also, the cGAS-STING pathway crosstalk with essential intracellular homeostasis processes like apoptosis, autophagy, and regulate cellular metabolism. Targeting derailed STING signaling has become necessary for chronic inflammatory diseases. Meanwhile, excessive type I interferons signaling impact on cardiovascular and metabolic health remain entirely elusive. In this review, we summarize the intimate connection between the cGAS-STING pathway and cardiovascular and metabolic disorders. We also discuss some potential small molecule inhibitors for the pathway. This review provides insight to stimulate interest in and support future research into understanding this signaling axis in cardiovascular and metabolic tissues and diseases.
8.Optimization of Smashing Tissue Extraction Technology of Schisandra chinensis Fruits by Orthogonal Test
Yun TANG ; Yanze LIU ; Ling HAN ; Yuqing ZHAO
Chinese Herbal Medicines 2012;04(3):259-262
Objective To optimize the extract technology of active lignins from the fruits of Schisandra chinensis.Methods The content of schizandrin,gomisin A,and deoxyschizandrin were selected as standards to evaluate the efficiency of smashing tissue extraction (STE).Solid-liquid ratio,extracting times,ethanol concentration,and extracting time were investigated through orthogonal test.Results The optimized conditions for STE were ten times amount of 80% EtOH,extracting for three times,and 2 min for each time.Conclusion STE could obtain relatively higher yield,simplicity of operation,and benefit for environment protection.It could be better choice for the extraction ofS.chinensis.
9.Smashing Tissue Extraction and GC Analysis of Active Fatty Acids from Oil Cake of Perilla Seeds
Yanling SUN ; Yanze LIU ; Han XIAO ; Yingfeng WEI ; Yuqing ZHAO
Chinese Herbal Medicines 2011;03(1):75-78
Objective To optimize the extraction technology of perilla seeds oil from the oil cake of perilla seeds (OCPS) by using the contents of active fatty acids as evaluation standard. Methods The fatty acids were extracted from OCPS,the residue of perilla seeds after cold-press, by smashing tissue extraction (STE), the new technology selected through comparing with classical leaching extraction (LE), Soxhlet extraction (SE), ultrasonic extraction (UE), and supercritical-CO2 fluid extraction (SFE). For optimized condition of STE, orthogonal test was designed and completed. The contents of five fatty acids in extracted oil and OCPS were determined by GC. Results The optimized extraction parameters were smashing for 1.5 min under extraction power of 150 W and 1:6 of the material/solvent ratio. The contents of five fatty acids in the oils extracted by five techniques from OCPS and determined by GC were as follows:a-linolenic acid (41.12%-51.81%), linoleic acid (15.38%-16.43%), oleic acid (18.93%-27.28010), stearic acid (2.56%-4.01%), and palmitic acid (7.38%-10.77%). Conclusion The results show that STE is the most efficient technology with the highest yield (LE:0.57%; SE:1.03%; UE:0.61%; SFE:0.8(r; STE:1.17%) and shortest time (LE:720 min; SE:360 min; UE:30 min; SFE:120 min; STE:1.5 min) among five tested extraction technologies. It is fast reported using STE to extract herbal oil enriched with active fatty acids.
10.Studies on chemical constituents of Chamaenerion angustifolium Ⅰ. Flavonoids from Chamaenerion angustifolium
Yanze LIU ; Caifang WANG ; Zhenzhong ZHANG ; Quanbin HAN ; Gang DING ;
Chinese Traditional and Herbal Drugs 1994;0(04):-
Object To study the chemical constituents of Chamaenerion angustifolium (L ) Scop Methods The compounds were isolated on Diaion HP 20 (Tsk), Toyoperari HW 40 (C), MCI gel CHP 20P (Mitsubishi) column and their structures were identified by physiochemical properties and spectral methods Results Four flavonoids were isolated from the whole plant of C angustifolium and they were identified as quercetin 3 O ? D galactoside (Ⅰ), quercetin 3 O ? L arabinoside (Ⅱ), quercetin 3 O (6′ O galloyl) ? D galactoside (Ⅲ), quercetin (Ⅳ) respectively Conclusion Compounds Ⅰ, Ⅱ, Ⅲ were isolated from this plant for the first time

Result Analysis
Print
Save
E-mail